Hepatitis virus and hepatocellular carcinoma;Virus de la hepatitis y carcinoma hepatocelular

Anales de Medicina Interna

Volumn 22, Issue 4, 2005, Pages 157-161

  Solis Herruzo J A ^a   Solis Munoz P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; VIRUS CARCINOGENESIS; VIRUS ETIOLOGY;

CARCINOMA, HEPATOCELLULAR; HEPATITIS, VIRAL, HUMAN; HUMANS; LIVER NEOPLASMS;

EID: 19544366609     PISSN: 02127199     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (77)

1. Anthony PP. Hepatocellular carcinoma: an overview. Histopathology 2001; 39: 109-118.
2. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37: S4-S66.
3. Bosch J, Ribes J, Borrás J. Epidemiology of Primary Liver cancer. Semin Liver Dis 1999; 19: 271-285.
4. Rodríguez-Vidigal FF, Baz MJ, Romero J, Del Puerto M. Epidemiología del carcinoma hepatocelular en un área rural. Papel de los virus hepatotropos en la supervivencia. An Med Interna (Madrid) 2005; 22: 162-166.
5. García-Torres ML, Zaragoza A, Giner R, Primo J, Olmo JA. Incidencia y factures epidemiológicos del carcinoma hepatocelular en Valencia durante el año 2000. Rev Esp Enferm Digest 2003; 95: 381-384.
6. Okuda K. Hepatocellular carcinoma. J Hepatol 2000; 32: 225-237.
7. Anthony PP. Hepatocellular carcinoma: an overview. Histopathology 2001; 39: 109-118.
8. Crespo J, Dueñas C, Sánchez-Antolín G, Fábrega E, Carte B, Pons-Romero F. Infección por el virus de la hepatitis B y C en pacientes con carcinoma hepatocelular. Med Clin (Barc) 1996; 106: 241-245.
9. Nguyen MH, Keefe EB. Screening for hepatocellular carcinoma J Clin Gastroenterol 2002; 35 (5 Supl. 2): S86-S91.
10. Bolondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellar carcinoma: a cost effectiveness analysis. Gut 2001; 48: 251-259.
11. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burrought AK, et al. Clinical management of hepatocellular carcinoma . J Hepatol 2001; 35: 421-430.
12. Solís-Herruzo JA. Hepatocellular carcinoma. Epidemiological and etiological factors. Rev Esp Enferm Digest 2003; 95: 377-380.
13. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998; 75: 347-354.
14. a edición. Zakim D, Boyer TD. Saunders. Philadelphia 2003; p. 959-1016.
15. Buendía MA Genetics of hepatocellular Carcinoma. Semin Cancer Biol 2000; 10: 185-200.
16. Wang Y, Lau SH, Sham JST, Wu MC, Wang T, Guan XY. Characterization of HBV integrants in 14 hepatocellular carcinomas: association of truncated X gene and hepatocellular carcinogenesis. Oncogene 2004; 23: 142-148.
17. Gozuacik D, Murakami Y, Saigo K, Chami M, Mugnier C, Lagorec D et al. Identification of human cancer-related genes by naturally occurring Hepatitis B Virus DNA tagging. Oncogene 2001; 20: 6233-6240.
18. Rogler CE, Chiasari FV. Cellular and molecular mechanisms of hepatocarcinogenesis. Semin Liver Dis 1992; 12: 265-78.
19. Urano Y, Watanabe K, Lin C, Hino O, Tamaoki T. Interstitial chromosomal deletion within 4q11-q13 in a human hepatoma cell line. Cancer Res 1991; 51: 1460-1464.
20. Chami M, Gozuacik D, Saigo K, Capiod T, Falson P, Lecoeur H et al. Hepatitis B virus-related insertional mutagenesis implicates SERCA1 gene in the control of apoptosis. Oncogene 2000; 19: 2877-2886.
21. Su TS, Hwang WL, Yauk YK. Usage of cryptic splice sites in citrullinemia fibroblasts suggests role of polyadenylation in splice-site selection during terminal exon definition. DNA Cell Biol 1998; 17: 415-425.
22. Brechot C, Gozuacik D, Murakami Y, Brechot PP. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol 2000; 10: 211-231.
23. Andrisani OM, Barnabas S. The transcriptional function of the hepatitis B virus X protein and its role in hepatocarcinogenesis. Int J Oncol 1999; 15: 373-379.
24. Nakatake H, Chisaka O, Yamamoto S, Matsubara K, Koshy R. Effect of X protein on transactivation of hepatitis B virus promoters and on viral replication. Virology 1993; 195: 305-314.
25. Arbuthnot P, Capovilla A, Kew M. Putative role of hepatitis B virus X protein in hepatocarcinogenesis: effects on apoptosis, DNA repair, mitogen-activated protein kinase and JAK/STAT pathways. J Gastroenterol Hepatol 2000; 15: 357-368.
26. Diao J, Garces R, Richardson CD. X protein of hepatitis B virus modulates cytokine and growth factor related signal transduction pathways during the course of viral infections and hepatocarcinogenesis. Cytokine Growth Factor Rev 2001; 12: 189-205.
27. Elmore LW, Hancock AR, Chang SF, Wang XW, Chang S, Callahan CP et al. Hepatitis B virus X protein and p53 tumor suppressor interaction in the modulation of apoptosis. Proc Natl Acad Sci USA. 1997; 94: 14707-14712.
28. Pan J, Duan LX, Sun BS, Feitelson MA. Hepatitis B virus X protein against anti-Fas-mediated apoptosis in human liver cells by inducing NF?B. J Gen Virol 2001; 82: 171-182.
29. Bergametti F, Prigent S, Lube B, Benoit A, Tiollais P, Sarasin A, Transy C. The proapoptotic effect of hepatitis B virus BHx protein correlates with its transactivation activity in stably transfected cell lines. Oncogene 1999; 18: 2860-2871.
30. Su F, Theodosis CN, Schneider RJ. Role of NFκB and myc proteins in apoptosis induced by hepatitis B HBx protein. J Virol 2001; 75: 215-225.
31. Kim H, Le H, Yun Y. X-gene product of hepatitis B virus induces apoptosis in liver cells. J Biol Chem 1998; 273: 381-385.
32. Kim YC, Song KS, Yoon G, Nam MJ, Ryu WS. Activated ras oncogene collaborates with HBx gene of hepatitis B virus to transform cell by suppressing HBx-mediated apoptosis. Oncogene 2001; 20: 16-23.
33. Yu DY, Moon HB, Son JK, Jeong S, Yu SL, Yoon H et al. Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein. J Hepatol 1999; 31: 123-132.
34. Bergametti F, Prigent S, Lube etc, Paterlini P, Poussin K, Kew M, Franco D, Brechot C. Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology 1995; 21: 313-321.
35. Chen WN, Oon CJ, Leong AL, Koh S, Teng SW. Expression of integrated hepatitis B virus variants in human hepatocellular carcinomas and its significance. Biochem Biophys Res Commun 2000; 276: 885-892.
36. Sirma H, Giannini C, Poussin K, Paterlini P, Kremdorf D, Brechot C. Hepatitis B virus, X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx. Oncogene 1999; 18: 4848-4859.
37. Tu H, Bonura C, Giannini C, Mouly H, Soussan P, Kew M et al. Biological impact of natural COOH-terminal deletion of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res 2001; 61: 7803-7810.
38. Harper JW, Adami GR, Wei NM, Keyomarsi W, Elledge SJ. The p21 CdK-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-6.
39. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J et al. WAF1/CIP1 is induced in p53-medieted G1 arrest and apoptosis. Cancer Res 1994; 54: 1169-1174.
40. El-Dairy WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
41. Wang XW, Gibson MK, Vermeulen W, Yeh H, Forrester K, Sturzbecher HW et al. abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res 1995; 55: 6012-6016.
42. Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induced liver cancer in transgenic mice. Nature 1991; 351: 317-320.
43. Ueda H, Ullrich SI, Gangemi JD, Kappel CA, Ngo L, Feitelson MA, et al. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet 1995; 9: 41-47.
44. Greenblatt MS, Feitelson MA, Zhu M, Bennett WP, Welsh JA, Jones R et al. Integrity of p53 in hepatitis Bx antigen-positive and -negative hepatocellular carcinomas. Cancer Res 1997; 57: 426-432.
45. Kobayashi S, Matsushita K, Saigo K, Urashima T, Asano T, Hayashi H et al. p21WAF1/CIP1 messenger RNA expression in hepatitis B, C virus-infected human hepatocellular carcinomas tissues. Cancer 2001; 91: 2096-2103.
46. Tu H, Bonura C. Giannini C, Mouly H, Soussan P, Kew M, et al. Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res 2001; 61: 7803-7810.
47. Provost E, Rimm DL Controversies at the cytoplasmic face of the cadherin-based adhesion complex Curr Opin Cell Biol 1999; 11: 567-572.
48. Jiang WG E-cadherin and its associated protein catenins, cancer invasion and metastasis. Hepatology 1996; 83: 437-446.
49. Barker N, Morin PL, Clevers H. The Yin-Yang of TCF/beta-catenin signaling. Adv Cancer Res 2000; 77: 1-24.
50. Polakis P. The oncogenic activation of β-catenin. Curr Opin Genet Dev 1999; 9: 15-21.
51. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. Beta-catenin is a target for the ubiquitin-proteosome pathway. EMBO J 1997; 16: 3797-3804.
52. Hart MJ, de los Santos R, Albert IN, Rubinfeld B, Polakis P. Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3?. Curr Biol 1998; 8: 573-581.
53. Behrens J, von Kries JP, Jul M, Bruhn L, Wedlich D, Grosschedl R et al. Functional interaction of β-catenin with the transcription factor LEF1. Nature 1996; 382: 638-642.
54. Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray. Cancer Res 2001; 61: 2129-2137.
55. Strassburg CP, Manns MP, Tukey RH. Differential down-regulation of the UDP-glucoronyltransferase 1A locus is an early event in human liver and biliary cancer. Cancer Res 1997; 57: 2979-2985.
56. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003: 139: 817-823.
57. Okuda K, Fujimoto I, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1998; 47: 4967-4972.
58. Di Bisceglie A. Hepatitis C and hepatocellular carcinoma. En: TJ Liang, JH Hoofnagle (eds.) Hepatitis C. Academic Press. San Diego 2000. pp 265-277.
59. Hsu HC, Jeng YM, Mao TL, Chu JS, Lai PL, Peng SY. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 2000; 157: 763-770.
60. Wong CM, Fan ST, Ng IOL. β-Catenin mutation and overexpression in hepatocellular carcinoma. Cancer 2001; 92: 136-145.
61. Kitagawa M, Hatakeyama S, Shirane M, Matsumoto M, Ishida N, Hattori K et al. An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of β-catenin. EMBO J 1999; 18: 2401-2410.
62. Muramatsu S, Ishido S, Fijita T, Itoh M. Hotta H. Nuclear localization of the N53 protein of hepatitis C virus and factors affecting the localization. J Virol 1997; 71: 4954-5961.
63. Ishido S, Hotta H. Complex formation of the nonstructural protein 3 of hepatitis C virus with the p53 tumor suppressor. FEBS Lett 1998; 438: 258-262.
64. Majunder M, Ghosh AK, Steele R, Ray R, Ray RB. Hepatitis C virus NS5A physically associated with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J Virol 2001; 75: 1401-1407.
65. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantvani F et al. Role of a p53 polymorphism in the development of human papiloma-virus-associated cancer. Nature 1998; 393: 229-234.
66. Anzola M, Cuevas N, López-Martínez M, Saiz A, Burgos JJ, Martínez de Pancorbo M. Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. Cancer Lett 2003; 193: 199-205.
67. Okada F, Shiraki T, Maekawa M, Sato S. A p53 polymorphism associated risk of hepatitis C virus infection. Cancer Lett 2001; 172: 137-142.
68. Leveri M, Gritti C, Rossi L, Zavaglia C, Civardi E, Mondelli MU, et al. Codon 72 polymorphism of p53 gene does not affect the risk of cirrhosis and hepatocarcinoma in HCV-infected patients. Cancer Lett. 2004; 208: 75-79.
69. Tanji Y, Kaneko T, Satoh S, Shimotohno K. Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. J Virol 1995; 69: 3980-3986.
70. He Y, Nakao H, Tan SL, Polyak PJ, Neddermann P, Vijaysri S, et al. Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase. J Virol 2002; 76: 9207-9217.
71. Street A, Macdonald A, Crowder K, Harris M. The hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase-dependent survival signaling cascade. J Biol Chem 2004; 279: 12232-12241.
72. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-1657.
73. Djordjevic S, Driscoll PC. Structural insight into substrate specificity and regulatory mechanisms of phosphoinositide 3-kinases. Trends Biochem Sci 2002; 27: 426-432.
74. Moriwaki H. Prevention of liver cancer: basis and clinical aspects. Exp. Mol Med 2002; 34: 319-325.
75. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997; 336: 1855-1859.
76. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1567-1570.
77. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: nacional surveillance programo f cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999; 131: 174-181.